If you have read anything about TB-500, it was probably about tendons, muscle tears or "accelerated healing". What almost never gets mentioned is that thymosin beta-4 — the natural protein TB-500 is derived from — actually does have a real, registered, late-stage human trial programme behind it. It just has nothing to do with injuries, and it isn't an injection. It's an eye drop. And in September 2026 it missed another primary endpoint.

That gap between where the human evidence actually sits and where the marketing points is the single most useful thing to understand about TB-500 research in Australia. Our full profile is at /peptides/tb-500; this post covers the trial programme most write-ups skip entirely.

What is TB-500, and what is actually being trialled?

Thymosin beta-4 (international non-proprietary name: timbetasin) is a 43-amino-acid actin-binding protein found throughout human tissue. TB-500, the product sold in research-chemical channels, is generally a short synthetic fragment based on the actin-binding region of that protein — a related but distinct molecule, which is why claims about one shouldn't be transplanted onto the other.

The clinical programme belongs to the full-length protein. Under the code RGN-259 — a preservative-free 0.1% ophthalmic solution developed by RegeneRx Biopharmaceuticals and its joint venture ReGenTree with Korea's HLB Therapeutics — thymosin beta-4 has been through Phase 2 and Phase 3 trials in two eye conditions: dry eye disease and neurotrophic keratopathy (also called neurotrophic keratitis), where corneal nerve damage stops the eye surface healing normally.

The Phase 3 that just missed

The story started well. SEER-1, a randomised, placebo-controlled, double-masked Phase 3 in neurotrophic keratopathy, was published in 2023. Complete corneal healing at four weeks occurred in 6 of 10 patients on RGN-259 versus 1 of 8 on placebo, with improvements in discomfort, foreign-body sensation and dryness. The one healed placebo patient relapsed by day 43; the treated group did not.

That is a striking effect size — and it came from 18 patients in total. Numbers that small are exactly where promising signals go to die, because a couple of patients shifting either way changes the headline. On the strength of it, the sponsors ran two 60-patient confirmatory Phase 3 trials, SEER-2 (US) and SEER-3 (Europe), in parallel.

In September 2026, trade press reported that SEER-3 failed to meet its primary endpoint: no statistically significant difference in complete corneal healing at four weeks versus placebo. The company attributed the result to a stronger-than-expected placebo response in the control arm. That explanation is plausible — corneal defects can heal on vehicle and intensive lubrication alone — but it is the sponsor's interpretation of topline data in a press announcement, not a peer-reviewed analysis. Treat it as such until the full dataset is published.

This has happened before

The dry eye programme followed the same arc. Phase 2 results were genuinely encouraging: at day 56, a 35.1% greater reduction in ocular discomfort and a 59.1% greater reduction in total corneal fluorescein staining versus vehicle. Then ARISE-3, the Phase 3, reported in 2021 that it did not meet its primary outcome measures. One pre-specified secondary symptom endpoint — ocular grittiness — did reach significance at several timepoints, and safety remained clean, with no serious adverse events.

Two indications, two well-run Phase 3 programmes, two primary-endpoint misses after positive earlier-phase data. That is not a scandal; it is ordinary drug development. But it is the actual state of the human evidence for thymosin beta-4, and it's a long way from "proven healing peptide".

Why the eye data can't be borrowed for injuries

Even if SEER-2 eventually succeeds, the read-across to injected TB-500 for a hamstring or a rotator cuff is close to zero:

  • Different molecule. The trials use full-length thymosin beta-4, not the short TB-500 fragment.
  • Different route and dose. A 0.1% drop applied topically five times daily to a 1cm² avascular surface is not a systemic subcutaneous injection.
  • Different endpoint. "Complete closure of a corneal epithelial defect on slit-lamp examination" is a hard, visible, measurable outcome. "Feels like my tendon recovered faster" is not.
  • Different comparator context. Neurotrophic keratitis already has an approved biologic, cenegermin, so the field is measuring against a real benchmark.

There are still no human trials supporting the injury-recovery use of TB-500. The musculoskeletal case rests on cell and animal work. That should be stated plainly, not buried.

Is TB-500 legal in Australia? The regulatory picture

Australia's position is unusually firm, and it predates all of this trial activity.

Following scheduling consideration in 2016, thymosin beta-4 and TB-500 sit in Schedule 4 and in Appendix D, Item 5 of the Poisons Standard. Appendix D, Item 5 is the strict tier: possession without authority — that is, other than in accordance with a valid prescription — is unlawful, not merely regulated at the point of sale. There is no registered thymosin beta-4 product on the ARTG for any indication, so in practice there is nothing lawful to be prescribed here.

The sports-law layer is equally settled. Thymosin beta-4 is prohibited at all times under the WADA Code as a growth factor, and in January 2016 the Court of Arbitration for Sport upheld anti-doping violations against 34 Essendon players in a case centred on it. Detection is no longer the obstacle it once was: LC-MS/MS methods for TB-500 and its metabolites have been published since 2012, with further equine and metabolite work since.

The instructive Australian contrast is the comparator drug. Cenegermin (Oxervate), a recombinant nerve growth factor eye drop, is registered on the ARTG (310960) for moderate-to-severe neurotrophic keratitis. That is what a completed evidence pathway looks like in this exact indication — trials, dossier, registration, product information. Thymosin beta-4 is trying to reach that bar and hasn't yet.

What to watch next

Three things worth tracking: whether SEER-2 in the US reports and what it shows; whether the SEER-3 data are published in full so the placebo-response explanation can be independently assessed; and whether any sponsor ever attempts a registered, randomised human trial of thymosin beta-4 or TB-500 for a musculoskeletal indication. Until that third one exists, the injury claims remain preclinical.

Browse the rest of our compound profiles at /peptides, or join the free updates list and we'll send trial readouts as they land — including whatever SEER-2 reports.

FAQ

What is TB-500 used for in research?

Preclinically it's studied for tissue repair, angiogenesis and anti-fibrotic effects. The only substantial human trial programme uses full-length thymosin beta-4 as an eye drop for dry eye and neurotrophic keratopathy — not as an injection for musculoskeletal injuries.

Is TB-500 legal in Australia?

No, not for personal use. Thymosin beta-4 and TB-500 are Schedule 4 and listed in Appendix D, Item 5 of the Poisons Standard, meaning possession without a valid prescription is unlawful — and no thymosin beta-4 product is registered on the ARTG.

Has TB-500 passed a Phase 3 trial?

Not yet. The RGN-259 (thymosin beta-4) eye drop missed its primary endpoint in the ARISE-3 dry eye Phase 3 in 2021 and in the SEER-3 neurotrophic keratopathy Phase 3 reported in September 2026, after a positive but very small 18-patient Phase 3 (SEER-1).

Is TB-500 banned in sport?

Yes. Thymosin beta-4 is prohibited at all times under the WADA Code as a growth factor, and validated mass-spectrometry detection methods for TB-500 and its metabolites have been published since 2012.

Sources

This article is independent editorial information, not medical advice. Thymosin beta-4 / TB-500 is not approved by the TGA for any indication, is Schedule 4 and Appendix D controlled in Australia, and is prohibited in sport; retatrutide.net.au does not sell or source peptides.